Zuranolone: Novel, Rapid-Acting Antidepressant Awaits FDA Approval
A New Drug Application for zuranolone awaits FDA approval for the treatment of major depressive disorder (MDD) and postpartum depression (PPD).
A New Drug Application for zuranolone awaits FDA approval for the treatment of major depressive disorder (MDD) and postpartum depression (PPD).
Peer support interventions can reduce the incidence of postpartum depression and the severity of depressive symptoms.
Depression and anxiety are prevalent among women who have experienced a stillbirth, especially those reporting inadequate paternal support
Announcing a new CWMH study on postpartum depression screening and treatment outcomes at Mass General Brigham.
Family history of psychiatric illness was associated a twofold increased risk for postpartum depression.
Family history of psychiatric, especially bipolar disorder, was associated with a signifiant increase in risk for postpartum depression.
Interested in telling your story or know of others who wish to share their PPD journey? We seek those who may be interested in participating in the documentary in some capacity.
Intravenous ketamine at delivery reduced risk for postpartum depression; however, only in women at high risk for PPD.
Intranasal oxytocin improves mood in postpartum women but has no impact on mood in women with more severe depressive symptoms.
About 60% of women with mood disorders experience premenstrual exacerbation or PME of their mood during the premenstrual phase of their cycle.